Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 — Veterans Health Administration, March

Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 — Veterans Health Administration, March–September 2022

Published:2024-01-25 Issue:3 Volume:73 Page:57-61
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Monach Paul A.,Anand Sonia T.,Fillmore Nathanael R.,La Jennifer,Branch-Elliman Westyn

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference9 articles.

1. National Institutes of Health. Coronovirus disease 2019 (COVID-19) treatment guidelines. Washington, DC: US Department of Health and Human Services, National Institutes of Health; 2023. https://www.covid19treatmentguidelines.nih.gov/

2. National Institutes of Health. COVID-19 treatment guidelines: anti-SARS-CoV-2 monoclonal antibodies. Washington, DC: US Department of Health and Human Services, National Institutes of Health; 2023. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/anti-sars-cov-2-monoclonal-antibodies/

3. CDC. COVID-19. Interim clinical considerations for COVID-19 treatment in outpatients. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. Accessed February 10, 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html

4. Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. Arlington, VA: Infectious Diseases Society of America; 2021. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#null

5. Anti–SARS-CoV-2 pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023.;Yan;JAMA Netw Open,2023